Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clinical pharmacokinetics

Showing results (1-10 of 3,805) with videos related to

Pageof 381
Sort By:
Clinical Pharmacokinetics|January 1, 1979
Factors influencing plasma concentrations of ethosuximideG A Smith, L McKauge, D Dubetz, et al.
Clinical Pharmacokinetics|March 1, 1979
Clinical pharmacokinetics of propranololP A Routledge, D G Shand
Clinical Pharmacokinetics|December 11, 2024
Correction: Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal CancerDaping Zhang, Adekemi Taylor, Jie Janet Zhao, et al.
Clinical Pharmacokinetics|December 4, 2014
Population pharmacokinetic modeling of Thymoglobulin(®) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosingRick Admiraal, Charlotte van Kesteren, Cornelia M Jol-van der Zijde, et al.
Clinical Pharmacokinetics|October 29, 2015
Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled StudyXia Zhao, Zining Wang, Yukun Wang, et al.
Clinical Pharmacokinetics|October 29, 2015
Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical TrialsJeanne S Geiser, Michael A Heathman, Xuewei Cui, et al.
Clinical Pharmacokinetics|October 29, 2015
Effects of Age, Sex, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of Azilsartan Medoxomil in Healthy SubjectsRobert E Harrell, Aziz Karim, Wencan Zhang, et al.
Clinical Pharmacokinetics|October 29, 2015
The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy VolunteersKari M Morrissey, Sophie L Stocker, Eugene C Chen, et al.
Clinical Pharmacokinetics|November 1, 2015
Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor VelpatasvirErik Mogalian, Polina German, Brian P Kearney, et al.
Clinical Pharmacokinetics|January 1, 1989
Unique aspects of quinolone pharmacokineticsH Lode, G Höffken, K Borner, et al.
Pageof 381

Showing results (1-10 of 3,805) with videos related to

Sort By:
Pageof 381
Clinical Pharmacokinetics|January 1, 1979
Factors influencing plasma concentrations of ethosuximideG A Smith, L McKauge, D Dubetz, et al.
Clinical Pharmacokinetics|March 1, 1979
Clinical pharmacokinetics of propranololP A Routledge, D G Shand
Clinical Pharmacokinetics|December 11, 2024
Correction: Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal CancerDaping Zhang, Adekemi Taylor, Jie Janet Zhao, et al.
Clinical Pharmacokinetics|December 4, 2014
Population pharmacokinetic modeling of Thymoglobulin(®) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosingRick Admiraal, Charlotte van Kesteren, Cornelia M Jol-van der Zijde, et al.
Clinical Pharmacokinetics|October 29, 2015
Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled StudyXia Zhao, Zining Wang, Yukun Wang, et al.
Clinical Pharmacokinetics|October 29, 2015
Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical TrialsJeanne S Geiser, Michael A Heathman, Xuewei Cui, et al.
Clinical Pharmacokinetics|October 29, 2015
Effects of Age, Sex, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of Azilsartan Medoxomil in Healthy SubjectsRobert E Harrell, Aziz Karim, Wencan Zhang, et al.
Clinical Pharmacokinetics|October 29, 2015
The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy VolunteersKari M Morrissey, Sophie L Stocker, Eugene C Chen, et al.
Clinical Pharmacokinetics|November 1, 2015
Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor VelpatasvirErik Mogalian, Polina German, Brian P Kearney, et al.
Clinical Pharmacokinetics|January 1, 1989
Unique aspects of quinolone pharmacokineticsH Lode, G Höffken, K Borner, et al.
Pageof 381